Vericel (VCEL) Change in Accured Expenses (2010 - 2026)
Vericel's (VCEL) quarterly Change in Accured Expenses came in at -$5.3 million in Q1 2026, down 639.3% year-on-year from $977000.0 in Q1 2025, and down 490.88% quarter-over-quarter from $1.3 million in Q4 2025.
Vericel (VCEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Vericel has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$5.3 million for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$5.3 million, down 639.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.1 million (down 158.0% YoY), and the FY2025 annual result was $2.2 million, up 1557.05% from the prior year.
- Change in Accured Expenses came in at -$5.3 million for Q1 2026 at Vericel, down from $1.3 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q2 2022 to a low of -$6.2 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $977000.0 (2025), against an average of -$66800.0.
- Across the five-year window, Change in Accured Expenses surged 7722.86% in 2024 and tumbled 639.3% in 2026, its largest moves.
- Vericel's Change in Accured Expenses stood at $2.1 million in 2022, then sank by 98.37% to $35000.0 in 2023, then soared by 7722.86% to $2.7 million in 2024, then slumped by 50.77% to $1.3 million in 2025, then tumbled by 490.88% to -$5.3 million in 2026.
- The last three Change in Accured Expenses figures came in at -$5.3 million (Q1 2026), $1.3 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -5.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.27 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 3.52 Mn |
| Sep 30, 2025 | 3.52 Mn |
| Jun 30, 2025 | -3.68 Mn |
| Jun 30, 2025 | -3.68 Mn |
| Mar 31, 2025 | 977,000.00 |
| Mar 31, 2025 | 977,000.00 |
| Dec 31, 2024 | 2.74 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Dec 31, 2023 | 35,000.00 |
| Dec 31, 2023 | 35,000.00 |